ResMed Announces SaaS Leadership Change
25 Agosto 2021 - 05:15PM
ResMed (NYSE: RMD, ASX: RMD), today announced the promotion of
Bobby Ghoshal to President of ResMed’s SaaS business, effective
immediately. Raj Sodhi will be leaving full-time employment at
ResMed, effective September 1.
Bobby has over 25 years of experience across medical and
technology industries, most currently serving as ResMed’s Chief
Technology Officer (CTO), with strong experience building and
leading high-performing teams to accelerate the adoption of digital
platforms across enterprises. From February 2016 until April 2018,
Bobby served as chief operating officer for Brightree, a
ResMed-owned provider of cloud-based software-as-a-service for
out-of-hospital care. ResMed will commence a search process for a
new CTO immediately; Bobby will remain in the CTO role until a
replacement is found.
“As we look ahead to 2025, we believe the future of healthcare
is outside the hospital and we have an amazing mission to improve
over 250 million lives,” said Mick Farrell, ResMed’s CEO. “We must
accelerate our efforts to bring software technology, along with
digital and commercial innovation, to these care settings. Digital
solutions, scalable digital platforms, and software embedded into
our customers’ workflows are critical to our growth strategy –
Bobby’s experience as ResMed’s CTO, his hands-on experience with
Brightree, and his strong background across many industries makes
him the right leader to accelerate our SaaS business to meet our
goals for 2025 and beyond.”
“I’d like to thank Raj for the incredible work he’s done over
the past nine years at ResMed,” continued Farrell. “Raj played an
important role in developing the healthcare informatics function at
ResMed, a function that helped to transform the company on our path
to becoming the leader in digital health. He also helped to craft
the SaaS strategy and lead multiple acquisitions that established
the foundation for us to scale and grow our SaaS business in home
medical equipment, skilled nursing facilities, home health,
hospice, private duty homecare, and beyond.”
About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we
pioneer innovative solutions that treat and keep people out of the
hospital, empowering them to live healthier, higher-quality lives.
Our digital health technologies and cloud-connected medical devices
transform care for people with sleep apnea, COPD, and other chronic
diseases. Our comprehensive out-of-hospital software platforms
support the professionals and caregivers who help people stay
healthy in the home or care setting of their choice. By enabling
better care, we improve quality of life, reduce the impact of
chronic disease, and lower costs for consumers and healthcare
systems in more than 140 countries. To learn more, visit
ResMed.com and follow @ResMed.
For
investors |
For
media |
Amy Wakeham |
Jayme Rubenstein |
+1 858.836.5000 |
+1 858.836.6798 |
investorrelations@resmed.com |
news@resmed.com |
ResMed (NYSE:RMD)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
ResMed (NYSE:RMD)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024